Graybill Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Graybill Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-164,358	Closed	-$1.95M	–	48
2017 Q2	$1.95M	Sell	164,358 -902	-0.5%	-$11.2K	1.54%	37
2017 Q1	$2.44M	Buy	165,260 +2,620	+2%	+$42.4K	1.94%	33
2016 Q4	$2.63M	Buy	162,640 +13,685	+9%	+$248K	2.25%	24
2016 Q3	$2.7M	Sell	148,955 -1,095	-0.7%	-$21.4K	2.51%	21
2016 Q2	$2.47M	Buy	+150,050	New	+$2.43M	2.29%	23

Other funds holding HZNP

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Graybill Wealth Management's HZNP Position: Q3 2017 in Review

Graybill Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 164,358 shares — an estimated $1.95M sold.

Graybill Wealth Management first reported a position in HZNP in Q2 2016 and held it in 5 quarters. The position peaked at $2.7M in Q3 2016. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

Graybill Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Graybill Wealth Management sold 164,358 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $1.95M.
Graybill Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 5 quarters.
Graybill Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.7M in Q3 2016.
181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on Graybill Wealth Management's 13F filing for Q3 2017, filed 18 Oct 2017.